Definium Therapeutics (DFTX) Research & Development (2019 - 2026)

Definium Therapeutics (DFTX) has 8 years of Research & Development data on file, last reported at $41.5 million in Q1 2026.

• Quarterly Research & Development rose 77.61% year-over-year to $41.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $135.8 million (up 76.51% YoY) and the FY2025 annual result came in at $117.7 million, up 80.25% from the prior year.
• Research & Development rose to $41.5 million in Q1 2026 per DFTX's latest filing, from $33.6 million in the prior quarter.
• Across five years, Research & Development topped out at $41.5 million in Q1 2026 and bottomed at $7.8 million in Q3 2022.
• The 5-year median for Research & Development is $14.6 million (2024), against an average of $18.4 million.
• The widest annual swing landed in 2022, when Research & Development declined 18.86%; it then soared 103.54% in 2025.
• Tracing DFTX's Research & Development over 5 years: stood at $8.8 million in 2022, then surged by 30.76% to $11.5 million in 2023, then surged by 88.48% to $21.8 million in 2024, then jumped by 54.2% to $33.6 million in 2025, then increased by 23.63% to $41.5 million in 2026.
• Per Business Quant, the three latest DFTX Research & Development figures stand at $41.5 million (Q1 2026), $33.6 million (Q4 2025), and $31.0 million (Q3 2025).

Peer Comparison